View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2021

Gland Pharma signs Sputnik V Covid-19 vaccine manufacturing deal with RDIF

Indian pharmaceutical company Gland Pharma has signed an agreement with the Russian Direct Investment Fund (RDIF) for the manufacture of nearly 252 million doses of the Sputnik V Covid-19 vaccine.

Indian pharmaceutical company Gland Pharma has signed an agreement with the Russian Direct Investment Fund (RDIF) for the manufacture of nearly 252 million doses of the Sputnik V Covid-19 vaccine.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Gland Pharma will use its manufacturing capabilities to produce and supply the vaccine.

According to the deal, the company will initially undertake the technology transfer of the drug substance to its facilities and will then manufacture the filled vials under aseptic conditions.

In a statement, the company said: “Gland Pharma’s expertise in manufacturing sterile injectable at a significant scale will support in establishing a stable supply of the Covid-19 vaccine.”

The Sputnik V vaccine production is scheduled for the third quarter of this year at the company’s drug substance and drug product facilities in Hyderabad, India, with estimated delivery in the fourth quarter of the year.

Derived from the human adenoviral vector-based platform, the Sputnik V vaccine uses two different vectors for the two shots of vaccination.

It provides immunity for longer than the vaccines with the same delivery mechanism for both shots.

Last month, the Egyptian Drug Authority (EDA) approved the Russian Direct Investment Fund’s (RDIF) Sputnik V under emergency use authorisation (EUA).

To date, Sputnik V has been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the UAE, Iran, the Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua and Republika Srpska (an entity of Bosnia and Herzegovina).

Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines (SVG), Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan and Guyana have also approved the vaccine.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology